卡介苗接种对2019冠状病毒病大流行期间老年人呼吸道感染的效果
这项多中心安慰剂对照试验将2014名60岁及以上老年人随机分配接受卡介苗皮内接种或安慰剂,随访12个月。卡介苗组需医疗干预的呼吸道感染累积发生率为0.029,对照组为0.024,亚分布风险比1.26(98.2%CI 0.65-2.44);两组SARS-CoV-2 PCR阳性分别为51例和48例,亚分布风险比1.053(95%CI 0.71-1.56)。卡介苗接种对呼吸道感染(包括SARS-CoV-2感染)发生率无影响,但增强了流感及SARS-CoV-2刺激后的细胞因子反应,并使COVID-19感染后抗体反应更强。
要点
- 卡介苗接种对老年人需医疗干预的呼吸道感染累积发生率无影响,亚分布风险比1.26(98.2%CI 0.65-2.44)。
- 卡介苗组与安慰剂组SARS-CoV-2 PCR阳性分别为51例和48例,亚分布风险比1.053(95%CI 0.71-1.56)。
- 卡介苗接种增强流感刺激后细胞因子反应,部分增强SARS-CoV-2刺激后反应,并增强COVID-19感染后抗体反应。
核心结论
- 卡介苗接种对老年人呼吸道感染(包括SARS-CoV-2感染)发生率无影响。
- 卡介苗接种改善了流感及SARS-CoV-2刺激后的细胞因子反应,并使COVID-19感染后抗体滴度更强。
研究设计与样本
- 多中心、安慰剂对照试验,随机分配60岁及以上老年人(n=2014)接受卡介苗皮内接种(n=1008)或安慰剂(n=1006)。
- 主要终点为12个月随访期间需医疗干预的呼吸道感染累积发生率。
- 次要终点包括COVID-19发生率及卡介苗对细胞和体液免疫反应的影响。
主要发现
- 需医疗干预的呼吸道感染累积发生率在卡介苗组为0.029,对照组为0.024,亚分布风险比1.26(98.2%CI 0.65-2.44)。
- 卡介苗组和安慰剂组分别有51例和48例SARS-CoV-2 PCR阳性,亚分布风险比1.053(95%CI 0.71-1.56)。
- 不良事件频率无差异。
- 卡介苗接种与流感刺激后细胞因子反应增强相关,与SARS-CoV-2刺激后反应部分相关。
- 在确诊COVID-19的患者中,若志愿者既往接种过卡介苗,感染后抗体反应显著更强。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Older age is associated with increased severity and death from respiratory infections, including coronavirus disease 2019 (COVID-19). The tuberculosis BCG vaccine may provide heterologous protection against nontuberculous infections and has been proposed as a potential preventive strategy against COVID-19. METHODS: In this multicenter, placebo-controlled trial, we randomly assigned older adults (aged ≥60 years; n = 2014) to intracutaneous vaccination with BCG vaccine (n = 1008) or placebo (n = 1006). The primary end point was the cumulative incidence of respiratory tract infections (RTIs) that required medical intervention, during 12 months of follow-up. Secondary end points included the incidence of COVID-19, and the effect of BCG vaccination on the cellular and humoral immune responses. RESULTS: The cumulative incidence of RTIs requiring medical intervention was 0.029 in the BCG-vaccinated group and 0.024 in the control group (subdistribution hazard ratio, 1.26 [98.2% confidence interval, .65-2.44]). In the BCG vaccine and placebo groups, 51 and 48 individuals, respectively tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with polymerase chain reaction (subdistribution hazard ratio, 1.053 [95% confidence interval, .71-1.56]). No difference was observed in the frequency of adverse events. BCG vaccination was associated with enhanced cytokine responses after influenza, and also partially associated after SARS-CoV-2 stimulation. In patients diagnosed with COVID-19, antibody responses after infection were significantly stronger if the volunteers had previously received BCG vaccine. CONCLUSIONS: BCG vaccination had no effect on the incidence of RTIs, including SARS-CoV-2 infection, in older adult volunteers. However, it improved cytokine responses stimulated by influenza and SARS-CoV-2 and induced stronger antibody titers after COVID-19 infection. CLINICAL TRIALS REGISTRATION: EU Clinical Trials Register 2020-001591-15 ClinicalTrials.gov NCT04417335.
引用
- Moorlag SJCFM, Taks E, Ten Doesschate T, et al. Efficacy of BCG Vaccination Against Respiratory Tract Infections in Older Adults During the Coronavirus Disease 2019 Pandemic. Clin Infect Dis. 2022. PMID: 35247264. doi:10.1093/cid/ciac182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。